SCHEMBL12803649

SCHEMBL12803649

Cc1cc2c(F)c(C#N)ccc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
ALDH1A1 P00352 3/20 0.39
GAA P10253 3/20 0.39
RXFP1 Q9HBX9 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PRKCQ Q04759 1/20 0.38
PRKCD Q05655 1/20 0.38
NQO2 P16083 1/20 0.37
HPGD P15428 3/20 0.37
CYP1A2 P05177 2/20 0.37
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2430502 0.79 MAOA (0.47) KEAP1NFE2L2ALDH1A1GAARXFP1
SCHEMBL2431816 0.79 AR (0.43) KEAP1NFE2L2ALDH1A1GAAKDM4E
SCHEMBL13744863 0.79 MEN1 (0.38) KEAP1NFE2L2ALDH1A1GAARXFP1
SCHEMBL12475636 0.76 KEAP1 (0.50) KEAP1NFE2L2ALDH1A1GAARXFP1
SCHEMBL370588 0.76 KEAP1 (0.50) KEAP1NFE2L2ALDH1A1GAARXFP1
SCHEMBL32889381 0.76 KEAP1 (0.50) KEAP1NFE2L2ALDH1A1GAARXFP1
SCHEMBL30265966 0.75 GAA (0.46) ALDH1A1GAARXFP1KDM4EMAPT
SCHEMBL5729594 0.75 GAA (0.46) ALDH1A1GAARXFP1KDM4EMAPT
SCHEMBL3393710 0.74 DAO (0.54)
SCHEMBL26278104 0.74 KEAP1 (0.38) KEAP1NFE2L2ALDH1A1GAARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252853-A1 Positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2012-10-04 US disclosed
WO-2012131031-A1 NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR H. LUNDBECK A/S (DK) 2012-10-04 WO disclosed
US-20120252853-A1 Positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2012-10-04 US disclosed
US-20120252853-A1 Positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2012-10-04 US disclosed
WO-2012131031-A1 NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR H. LUNDBECK A/S (DK) 2012-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252853-A1 Positive allosteric modulators of nicotinic acetylcholine receptor CHRNG, CHRNA7, CHRNA2 KEAP1 2164/4885NFE2L2 4098/4885ALDH1A1 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.